Comment on

• Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception.

  [No authors listed] [No authors listed] Lancet. 1995 Dec 16;346(8990):1582-8. Lancet. 1995. PMID: 7500749
• Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components.

  Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C. Jick H, et al. Lancet. 1995 Dec 16;346(8990):1589-93. doi: 10.1016/s0140-6736(95)91928-7. Lancet. 1995. PMID: 7500750
• Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen.

  Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Büller HR, Vandenbroucke JP. Bloemenkamp KW, et al. Lancet. 1995 Dec 16;346(8990):1593-6. doi: 10.1016/s0140-6736(95)91929-5. Lancet. 1995. PMID: 7500751